SecBot SecBot
SECBOTREPLAY Home › Report › LGND

LGND · Ligand Pharmaceuticals issued $700M of 0.00% Convertible Senior Notes…

LIGAND PHARMACEUTICALS INC · 8-K filed Jun 25, 2026 at 17:00 ET

At the news

MIXEDIMPACT 6/10

8-K filed Jun 25, 2026 at 17:00 ET

Ligand Pharmaceuticals issued $700M of 0.00% Convertible Senior Notes due 2031, with an initial conversion price of approximately $334.27 per share, and concurrently entered into a bond hedge (capped call) and warrant transactions to manage dilution. The proceeds are intended to help fund the pending acquisition of XOMA Royalty Corporation. The capital raise introduces dilution risk but is partially offset by the bond hedge, while the warrants add additional potential dilution if the stock exceeds the strike price.

  • Issued $700,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2031
  • Initial conversion rate of 2.9916 shares per $1,000 principal, equating to an initial conversion price of ~$334.27 per share
  • Notes are zero-coupon and mature on September 15, 2031
  • Bond hedge (capped call) and warrant transactions entered into with dealers to manage dilution and provide additional upside exposure

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access